Citations

Clear

2416 citation(s) found for "Yu, Jason L".

Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and “Sweet Pee Encephalopathy” in Perioperative Hospital Management
Mackintosh, Christopher, Tewari, Arti , Siegel, Jason , Wang, R Doris, Freeman, William T. , Freeman, William, Freeman, William

Mayo Clinic

The Neurohospitalist | March 7, 2019 | Volume: 10 | Issue: 1 | Pages: 51-54

10.1177/1941874419835035 | PMID 31839866 Get It

During preanesthesia evaluation, patient medications are reviewed and many are not administered on the day of surgery. Additionally, neurosurgical patients can develop postoperative encephalopathy from a variety of etiologies, including metabolic derangements. We report a case of postoperative neurosurgical euglycemic ketoacidosis which presented as unexplained encephalopathy and was the result of continued action of the patient’s serum glucose cotransporter-2 (SGLT-2) inhibitor combined with perioperative fasting. A 68-year-old woman with a history of type 2 diabetes mellitus was admitted to the neurocritical care service after resection of a left temporal meningioma. On postop day 1, she became lethargic and with worsening aphasia. Laboratory studies revealed blood glucose 140 to 160 mmol/L, bicarbonate 9 mmol/L, anion gap of 21, and pH of 7.2. Urine was positive for ketones and glucose, and serum was positive for β-hydroxybutyrate. Endocrinology was consulted and the patient was diagnosed with euglycemic diabetic ketoacidosis and treated with insulin until her anion gap closed. Over the next 2 days, her neurological examination improved to baseline. Although the patient did not take empagliflozin the day of surgery, the drug has a half-life of >12 hours, and other reports have described continued glycosuria for up to 10 days after drug discontinuation. This case illustrates the need for increased awareness of SGLT-2 inhibitors and “sweet pee encephalopathy” among neurosurgical and neurointensivist teams as well as potential modification of perioperative management of patients using newly emerging SGLT-2 inhibiting pharmaceuticals.
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, Suzanne E. , Li, Yan , Todd, Kaitlin , Herries, Elizabeth, Henson, Rachel L. , Gray, Julia, Wang, Guoqiao , Graham, Danielle , Shaw, Leslie M. , Trojanowski, John Q. , Hassenstab, Jason , Benzinger, Tammie L.S. , Cruchaga, Carlos , Xiong, Chengjie , Chhatwal, Jasmeer P. , Noble, James M. , Ringman, John M. , Graff‐Radford, Neill R. , Ladenson, Jack H., Morris, John C. , Bateman, Randall J. , Fagan, Anne M. , Network, Dominantly Inherited Alzheimer, Fox, Nick C. , Cruchaga, Carlos , Bateman, Randall J , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , Holtzman, David M. , Xiong, Chengjie , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | March 4, 2019 | Volume: 15 | Issue: 5 | Pages: 655-665

10.1016/j.jalz.2018.12.019 | PMID 30846386 Get It

AbstractIntroductionFour less well‐studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late‐onset Alzheimer disease (AD): neurogranin, synaptosomal‐associated protein‐25 (SNAP‐25), visinin‐like protein 1 (VILIP‐1), and chitinase‐3‐like protein 1 (YKL‐40).MethodsCSF neurogranin, SNAP‐25, VILIP‐1, and YKL‐40 were measured in families carrying autosomal‐dominant AD mutations.ResultsThe four emerging CSF biomarkers were significantly elevated in the mutation carriers (n = 235) versus noncarriers (n = 145). CSF SNAP‐25, VILIP‐1, and YKL‐40 were altered very early in the AD time course, approximately 15–19 years before estimated symptom onset. All CSF biomarkers predicted important AD‐related outcomes including performance on a cognitive composite, brain amyloid burden as measured by amyloid positron emission tomography, and the estimated years from symptom onset.DiscussionEarly abnormalities in CSF tTau, pTau, SNAP‐25, VILIP‐1, and YKL‐40 suggest that synaptic damage, neuronal injury, and neuroinflammation begin shortly after the commencement of brain amyloid accumulation.
Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis
McCarthy, Cormac , Bartholmai, Brian J. , Woods, Jason C. , McCormack, Francis X. , McCormack, Francis X , Bartholmai, Brian J , Trapnell, Bruce C.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 1, 2019 | Volume: 199 | Issue: 9 | Pages: 1151-1152

10.1164/rccm.201810-1918im | PMID 30822107 Get It

Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group
Mahadevan, Uma , Bernasko, Nana, Boland, Brigid S. , Dubinsky, Marla C. , Friedman, Sonia , Kane, Sunanda V. , Manthey, Jacob, Sauberan, Jason , Robinson, Christopher James , Chambers, Christina , Stone, James L. , Jain, Rajeev Kumar , Friedman, Sonia

Mayo Clinic

Inflammatory Bowel Diseases | March 1, 2019 | Volume: 25 | Issue: 4 | Pages: 627-641

10.1093/ibd/izz037 | PMID 30821832 Get It

Privacy in Direct-to-Consumer Genetic Testing
Risher, Michael T, Baudhuin, Linnea M. , Schwab, Abraham, Park, Jason Y. , Risher, Michael T., Caulfield, Timothy

Mayo Clinic

Clinical Chemistry | February 28, 2019 | Volume: 65 | Issue: 5 | Pages: 612-617

10.1373/clinchem.2018.298935 | PMID 30819664 Get It

Preadmission Corticosteroid Therapy and the Risk of Respiratory Failure in Adults Without HIV Presenting With Pneumocystis Pneumonia
Wieruszewski, Patrick M. , Frazee, Erin N. , Barreto, Jason N. , Yadav, Hemang , Tosh, Pritish K. , Mara, Kristin C. , Mara, Kristin C , Wieruszewski, Patrick M , Limper, Andrew H.

Mayo Clinic

Journal of Intensive Care Medicine | February 28, 2019 | Volume: 35 | Issue: 12 | Pages: 1465-1470

10.1177/0885066619834242 | PMID 30813829 Get It

Background: Corticosteroid therapy is a well-recognized risk factor for Pneumocystis pneumonia (PCP); however, it has also been proposed as an adjunct to decrease inflammation and respiratory failure. Objective: To determine the association between preadmission corticosteroid use and risk of moderate-to-severe respiratory failure at the time of PCP presentation. Methods: This retrospective cohort study evaluated HIV-negative immunosuppressed adults diagnosed with PCP at Mayo Clinic from 2006 to 2016. Multivariable regression models were used to evaluate the association between preadmission corticosteroid exposure and moderate-to-severe respiratory failure at presentation. Results: Of the 323 patients included, 174 (54%) used preadmission corticosteroids with a median daily dosage of 20 (interquartile range: 10-40) mg of prednisone or equivalent. After adjustment for baseline demographics, preadmission corticosteroid therapy did not decrease respiratory failure at the time of PCP presentation (odds ratio: 1.23, 95% confidence interval: 0.73-2.09, P = .38). Additionally, after adjusting for inpatient corticosteroid administration, preadmission corticosteroid use did not impact the need for intensive care unit admission ( P = .98), mechanical ventilation ( P = .92), or 30-day mortality ( P = .11). Conclusions: Corticosteroid exposure before PCP presentation in immunosuppressed HIV-negative adults was not associated with a reduced risk of moderate-to-severe respiratory failure.
Fate of the Fontan connection: Mechanisms of stenosis and management
Hagler, Donald J. , Miranda, William R. , Haggerty, Brielle J., Johnson, Jonathan N. , Cetta, Frank , Said, Sameh M. , Taggart, Nathaniel W. , Anderson, Jason H. , Johnson, Jonathan , Taggart, Nathaniel W

Mayo Clinic

Congenital Heart Disease | February 26, 2019 | Volume: 14 | Issue: 4 | Pages: 571-581

10.1111/chd.12757 | PMID 30801968 Get It

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer’s disease
Vöglein, Jonathan , Paumier, Katrina L. , Preische, Oliver, Hassenstab, Jason , Benzinger, Tammie L.S. , Noble, James M. , Berman, Sarah , Graff‐Radford, Neill R. , Farlow, Martin R. , Chhatwal, Jasmeer P. , Salloway, Stephen , Xiong, Chengjie , Cairns, Nigel J., Mori, Hiroshi , Masters, Colin L. , Goate, Alison , Buckles, Virginia, Fox, Nick C. , Chrem, Patricio, Allegri, Ricardo , Ringman, John M. , Höglinger, Günter U. , Steiner, Harald , Dieterich, Marianne , Haass, Christian , Laske, Christoph , Morris, John C. , Bateman, Randall J. , Danek, Adrian , Network, Dominantly Inherited Alzheimer, Höglinger, Günter U , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , McDade, Eric , Ghetti, Bernardino , Xiong, Chengjie , Karch, Celeste M. , Schofield, Peter R. , Rossor, Martin N. , Network, Dominantly Inherited Alzheimer, Goate, Alison M , Allegri, Ricardo , Berman, Sarah , Noble, James M

Mayo Clinic

Brain | February 25, 2019 | Volume: 142 | Issue: 5 | Pages: 1429-1440

10.1093/brain/awz050 | PMID 30897203 Get It

Aβ deposition in the basal ganglia is common in autosomal dominant Alzheimer’s disease. Vöglein et al. report an increased severity of motor symptoms in autosomal dominant versus sporadic disease in advanced disease stages. Motor symptoms are more severe in post-codon 200 presenilin 1 mutation carriers and correlate with basal ganglia Aβ.
Spleen Tyrosine Kinase–Mediated Autophagy Is Required for Epithelial–Mesenchymal Plasticity and Metastasis in Breast Cancer
Shinde, Aparna , Hardy, Shana D., Akhand, Saeed Salehin , Anderson, Joshua C. , Khodadadi, Ryan B. , Brown, Wells S. , George, Jason T. , Liu, Sheng , Wan, Jun , Levine, Herbert , Krusemark, Casey J. , Wendt, Michael K. , Anderson, Joshua C , Khodadadi, Ryan B , Willey, Christopher D , Wendt, Michael K , Wan, Jun , Kim, Dong Wook , Jolly, Mohit Kumar , Wang, Wen‐Hung , Geahlen, Robert L.

Mayo Clinic

Cancer Research | February 7, 2019 | Volume: 79 | Issue: 8 | Pages: 1831-1843

10.1158/0008-5472.can-18-2636 | PMID 30733195 Get It

Abstract The ability of breast cancer cells to transiently transition between epithelial and mesenchymal states contributes to their metastatic potential. Therefore, driving tumor cells into a stable mesenchymal state, as opposed to complete tumor cell eradication, presents an opportunity to pharmacologically limit disease progression by promoting an asymptomatic state of dormancy. Here, we compare a reversible model of epithelial–mesenchymal transition (EMT) induced by TGFβ to a stable mesenchymal phenotype induced by chronic exposure to the ErbB kinase inhibitor lapatinib. Only cells capable of returning to an epithelial phenotype resulted in skeletal metastasis. Gene expression analyses of the two mesenchymal states indicated similar transition expression profiles. A potently downregulated gene in both datasets was spleen tyrosine kinase (SYK). In contrast to this similar diminution in mRNA, kinome analyses using a peptide array and DNA-conjugated peptide substrates showed a robust increase in SYK activity upon TGFβ-induced EMT only. SYK was present in cytoplasmic RNA processing depots known as P-bodies formed during the onset of EMT, and SYK activity was required for autophagy-mediated clearance of P-bodies during mesenchymal–epithelial transition (MET). Genetic knockout of autophagy-related 7 (ATG7) or pharmacologic inhibition of SYK activity with fostamatinib, a clinically approved inhibitor of SYK, prevented P-body clearance and MET, inhibiting metastatic tumor outgrowth. Overall, this study suggests assessment of SYK activity as a biomarker for metastatic disease and the use of fostamatinib as a means to stabilize the latency of disseminated tumor cells. Significance: These findings present inhibition of spleen tyrosine kinase as a therapeutic option to limit breast cancer metastasis by promoting systemic tumor dormancy. See related commentary by Farrington and Narla, p. 1756